Women in Biotech - London
The Peri-Pandemic Workplace in Biotech
As the workplace shifts in line with pandemic precautions, new logistical challenges, new opportunities and expectations, we’ll be exploring revised attitudes towards work and employment in the life sciences. How are companies communicating cultural adaptations at work both internally and externally, and how might these changes impact different groups positively or negatively within the workforce? Our panel will discuss implications from small biotech and pharma perspectives, and will incorporate legal and communication strategy/input.
Join us for this in-person WIB and live panel: come and engage, hear from our inspiring panellists, renew existing acquaintances, and build your network over a glass of wine!
One Nucleus Genesis
This event is part of the One Nucleus Genesis fringe week. One Nucleus members are eligble to book this event at the BIA member rate, please contact Aline@onenucleus.com for further information.
17:30 Registration & networking
18:10 Panel and Q&A with
Elizabeth Lang, Partner, UK, Bird & Bird
Jacqui Hall, Head of Early Careers, BioPharma R&D, AstraZeneca
Professor Claire Thompson, CEO, Agility Life Sciences
Ola Wlodek, COO, Reflection Therapeutics
19:00 Networking and drinks reception
BIA members - £30 +VAT
Non-members - £40 +VAT
By registering to this event you accept our Terms & Conditions
VENUE AND EVENT ACCESSIBILITY
We are regularly monitoring changes on government regulations around events. All delegates will be asked to provide a negative covid test result (taken in the last 24h) closer to the event. Alternative or additional precautions like the wearing of masks inside the venue might also be considered and requested.
If you have any questions or problems registering, please contact Sam Care - SCare@bioindustry.org
Elizabeth is a partner specialising in employment law. She is based in the Bird & Bird London office but works as part of the International HR Services team. She works for a wide range of clients, companies, and individuals, advising on a wide range of issues, helping them to resolve employment law issues.
Elizabeth often advises clients on strategic HR related issues such as how to implement new legislation and how to prepare for future changes on the horizon, as well as advising on specific employment related issues such as dismissals, investigations, employee claims, and restructurings. A typical week may involve negotiating severance packages with senior executives, advising on a factory closure, working on a union recognition dispute, changing terms and conditions, or negotiating a TUPE schedule. She also acts for clients in Employment Tribunal proceedings, appeals to the Employment Appeals Tribunal, the High Court and the Court of Appeal.
Her approach is highly practical and constructive, and she believes that the best results come from working collaboratively with clients. She has a large number of long-standing clients that know that she will always seek to give service of the highest quality in the most efficient way possible. This includes evaluating at an early stage whether there is a way to minimise time and cost expenditure.
Jacqui joined Cambridge Antibody Technology (later MedImmune, then AstraZeneca) in 2006 to establish a project leadership and management group. Following reorganisation in 2010, Jacqui led a number of change initiatives to establish principles for the transition of medicines from early to late-stage clinical development. In 2011, Jacqui set up the Scientific Learning team at MedImmune, responsible for scientific training, as well as wider learning and development.
In her current role at AstraZeneca, Jacqui leads the Early Careers team in Research and Development, focussed on building global, high quality programmes for apprentices, graduates, undergraduates, PhD students and post-doctoral researchers. She is a Board member of the Science Industry Partnership and leads the Futures group for skills delivery. She is also a member of the UKRI-BBSRC People and Talent Strategy Advisory Panel.
Prior to joining AstraZeneca, Jacqui spent over 17 years working in clinical development and project leadership roles at Schering-Plough, PPD and GlaxoSmithKline.
Jacqui holds a first class honours degree in Chemistry from the University of London and a postgraduate diploma in Clinical Science from the University of Wales. She is a fellow of the Royal Society of Biology and the Institute of Innovation and Knowledge Exchange.
Professor Claire Thompson
Claire is a multi-award winning scientist, strategist and storyteller with more than 20 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual biotech and Contract Development and Manufacturing Organisations (CDMOs). She is CEO of Agility Life Sciences, an award-winning CDMO, consulting and communications firm which works with organisations across the healthcare space to fast track their products to market, raise investment and help them to convey the benefits of their science through impactful communications.
Agility supports biotech clients across the globe in developing formulations for novel drug candidates (small molecules and biologicals) for various routes of administration including oral, ocular, IV, intranasal and topical. Agility’s “Fast Futureproof Formulations” approach means they always start with an end in mind, developing products which enable molecules to be accelerated from discovery to clinic.
Claire is also Entrepreneur in Residence at the University of Cambridge, where she advises academics on how to translate their research into healthcare products, develop strategic partnerships and source funding. She holds an Honorary Professorship from the School of Pharmacy at the University of Nottingham, and is Chair of the International Pharmaceutical Federation’s Women in Science and Education (FIP WiSE) initiative.
Ola Wlodek, a Chief Operating Officer at Reflection Therapeutics, has a PhD in biological sciences from Cambridge University and studies executive MBA at Warwick Business School. After her PhD, she worked in various companies within the Cambridge cluster. She co-founded Reflection Therapeutics to develop a new CAR-Treg therapy for amyotrophic lateral sclerosis.
Thank you to our host and Women in Biotech series supporter